MX386295B - Mutante cd200 y sus usos - Google Patents

Mutante cd200 y sus usos

Info

Publication number
MX386295B
MX386295B MX2018013778A MX2018013778A MX386295B MX 386295 B MX386295 B MX 386295B MX 2018013778 A MX2018013778 A MX 2018013778A MX 2018013778 A MX2018013778 A MX 2018013778A MX 386295 B MX386295 B MX 386295B
Authority
MX
Mexico
Prior art keywords
protein
relates
mutant
mutated
mutation
Prior art date
Application number
MX2018013778A
Other languages
English (en)
Spanish (es)
Other versions
MX2018013778A (es
Inventor
Jonathan Heal
Joseph Sheridan
Philip Huxley
Original Assignee
Ducentis Biotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ducentis Biotherapeutics Ltd filed Critical Ducentis Biotherapeutics Ltd
Publication of MX2018013778A publication Critical patent/MX2018013778A/es
Publication of MX386295B publication Critical patent/MX386295B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2018013778A 2016-05-10 2017-05-10 Mutante cd200 y sus usos MX386295B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1608197.8A GB201608197D0 (en) 2016-05-10 2016-05-10 Novel proteins
PCT/GB2017/051303 WO2017194941A1 (en) 2016-05-10 2017-05-10 Cd200 mutant and its uses

Publications (2)

Publication Number Publication Date
MX2018013778A MX2018013778A (es) 2019-08-01
MX386295B true MX386295B (es) 2025-03-18

Family

ID=56297468

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018013778A MX386295B (es) 2016-05-10 2017-05-10 Mutante cd200 y sus usos

Country Status (16)

Country Link
US (1) US11203628B2 (enExample)
EP (1) EP3455247A1 (enExample)
JP (1) JP6997767B2 (enExample)
KR (2) KR102498901B1 (enExample)
CN (1) CN109219614B (enExample)
AU (1) AU2017264825B2 (enExample)
BR (1) BR112018073280A2 (enExample)
CA (1) CA3023601A1 (enExample)
EA (1) EA201892554A1 (enExample)
GB (1) GB201608197D0 (enExample)
IL (1) IL262846B2 (enExample)
MX (1) MX386295B (enExample)
NZ (1) NZ747665A (enExample)
SG (1) SG11201809677XA (enExample)
WO (1) WO2017194941A1 (enExample)
ZA (1) ZA201807079B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201608197D0 (en) 2016-05-10 2016-06-22 Ducentis Biotherapeutics Ltd Novel proteins
KR102186780B1 (ko) 2019-02-18 2020-12-04 박주현 비행부와 탑승부를 분리하여 축으로 결합한 유인드론
CN110859951A (zh) * 2019-09-23 2020-03-06 中国药科大学 Cd200蛋白和cd200融合蛋白在制备治疗银屑病药物中的应用
GB202115803D0 (en) * 2021-11-03 2021-12-15 Ducentis Biotherapeutics Ltd Novel proteins
KR20250025619A (ko) * 2022-05-06 2025-02-24 두센티스 바이오테라퓨틱스 리미티드 신규한 cd200 융합 단백질
WO2023214387A1 (en) * 2022-05-06 2023-11-09 Ducentis Biotherapeutics Limited Novel cd200 fusion proteins
GB2626300A (en) * 2022-12-08 2024-07-24 Ducentis Biotherapeutics Ltd Mutated CD200 proteins and methods of use therof
GB202303291D0 (en) 2023-03-07 2023-04-19 Secr Defence Medicament and medicament combination for use in the treatment of infectious disease
GB202306711D0 (en) * 2023-05-05 2023-06-21 Ducentis Biotherapeutics Ltd Novel proteins
WO2025106841A1 (en) * 2023-11-15 2025-05-22 The University Of Chicago Methods and compositions for inducing antigen specific tolerance

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223729B2 (en) 1997-11-07 2007-05-29 Trillium Therapeutics Inc. Methods of treating allergy by administering a CD200 protein
DK1032662T3 (da) * 1997-11-07 2006-07-03 Trillium Therapeutics Inc Fremgangsmåder og sammensætninger til immunmodulation
MXPA01010480A (es) * 1999-04-13 2002-03-27 Schering Corp Usos novedosos de la proteina 0x2 de mamifero y reactivos relacionados.
EP1261743A2 (en) * 2000-03-07 2002-12-04 Hyseq, Inc. Novel nucleic acids and polypeptides
AU2333802A (en) * 2000-11-22 2002-06-03 Transplantation Technologies I Truncated cd200
TWI323734B (en) * 2005-08-19 2010-04-21 Abbott Lab Dual variable domain immunoglobulin and uses thereof
CA2674578A1 (en) * 2007-01-11 2008-07-24 Boehringer Ingelheim International Gmbh Cd200 and its receptor, cd200r, modulate bone mass via the differentiation of osteoclasts
EP2414385B1 (en) * 2009-03-31 2015-04-22 University of Washington Compositions and methods for modulating the activity of complement regulatory proteins on target cells
EP2523976B1 (en) * 2010-01-11 2018-04-25 Alexion Pharmaceuticals, Inc. Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
GB201608197D0 (en) 2016-05-10 2016-06-22 Ducentis Biotherapeutics Ltd Novel proteins

Also Published As

Publication number Publication date
KR102498901B1 (ko) 2023-02-10
KR102689460B1 (ko) 2024-07-26
JP6997767B2 (ja) 2022-03-04
GB201608197D0 (en) 2016-06-22
EP3455247A1 (en) 2019-03-20
AU2017264825A1 (en) 2018-11-15
BR112018073280A2 (pt) 2019-03-19
US20190367580A1 (en) 2019-12-05
ZA201807079B (en) 2019-07-31
IL262846B (en) 2022-10-01
NZ747665A (en) 2025-10-31
WO2017194941A1 (en) 2017-11-16
CN109219614B (zh) 2022-05-24
EA201892554A1 (ru) 2019-04-30
MX2018013778A (es) 2019-08-01
SG11201809677XA (en) 2018-11-29
CN109219614A (zh) 2019-01-15
IL262846B2 (en) 2023-02-01
IL262846A (en) 2018-12-31
JP2019518788A (ja) 2019-07-04
CA3023601A1 (en) 2017-11-16
KR20190003761A (ko) 2019-01-09
KR20230025937A (ko) 2023-02-23
AU2017264825B2 (en) 2021-04-08
US11203628B2 (en) 2021-12-21

Similar Documents

Publication Publication Date Title
MX386295B (es) Mutante cd200 y sus usos
NZ748307A (en) Gdf15 fusion proteins and uses thereof
IL276469A (en) Non-viral DNA vectors and their uses for the production of antibody and fusion protein
PH12018500657A1 (en) Optimized variants of anti-vegf antibodies
BR112016014810A2 (pt) Antagonistas de fcrn e métodos de uso
CY1122494T1 (el) Πρωτεϊνες συντηξης οι οποιες περιλαμβανουν μια πρωτεϊνη δεσμευσης και ενα πολυπεπτιδιο ιντερλευκινης-15 το οποιο εχει μια μειωμενη συγγενεια για il15ra και θεραπευτικες χρησεις αυτων
MX389878B (es) Proteinas quimericas de factor viii y usos de estas.
AR099288A1 (es) Proteínas de fusión de interleucina-10
SG10201808523RA (en) Il-22 polypeptides and il-22 fc fusion proteins and methods of use
HK1200842A1 (en) Proteins with improved half-life and other properties
MX2021000030A (es) Metodos y composiciones que utilizan polipeptidos variantes klotho.
PE20171652A1 (es) Nuevas proteinas especificas para pioverdina y pioquelina
EP4085077A4 (en) Fusion proteins of glp-1 and gdf15 and conjugates thereof
NZ751983A (en) Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof
MA43348A (fr) Conjugués de protéines
FR3001729B1 (fr) Mutants du facteur x
MX2025013204A (es) Proteinas de fusion cd200
HK40040281A (en) Non-viral dna vectors and uses thereof for antibody and fusion protein production